Vinca Alkaloids for Idiopathic Thrombocytopenic Purpura

  1. MADHAVAN V. PILLAI, M.D.;
  2. CORY D. SPENCER, M.D.; and
  3. TAKUO SONODA, M.D.
  1. Andrews Air Force Base; MD 20335
  2. Laurel, MD 20707
  3. Fort Washington, MD 20744

    Excerpt

    To the editor: Ahn and coworkers (1) have reported interesting observations on the results of slow infusion of vinca alkaloids in the treatment of idiopathic thrombocytopenic purpura. However, several points crucial for an objective analysis are not clarified in their data. Although the authors define "excellent" and "good" responses, the pretreatment platelet counts are not mentioned for these patients. It is very important to specify what the precise pretreatment was. Obviously, a rise to 130 000/mm3 from 120 000/mm3 or 20 000/mm3 have different implications.

    Emphasis on the numerical correction of platelet counts in asymptomatic patients with chronic idiopathic thrombocytopenic

    This 100-word excerpt has been provided in the absence of an abstract.

    « Previous | Next Article »Table of Contents